Synthetic haemoglobin is a breakthrough technology in both the biotech (aerobic cell agriculture) and medtech (treatment of anoxia, stroke, infarction, pulmonary insufficiency, arteriopathy of the limbs, etc.) fields.
| Target |
A$720,000
|
| Minimum |
A$14,000
|
| Investment Raised | N/A |
| Previous Rounds | N/A |
| Stage | Pre-Startup/R&D |
| Investor Role | Any |
location_on South East, United Kingdom
Lifelancer is building a SaaS-based Freelance & Remote Job Platform in Life Science, IT & Digital Health; $5bn+ global market; Team size 10+; 45+ yrs team experience; MVP launched (www.lifelancer.net); Grants + Investment (£150K+); SEIS + EIS
• Addressing the unmet need in fast growing $5 billion global market
• High growth international SaaS business, COVID proof, remote & cloud-based
location_on Geneva, Switzerland
Biomedicine Longevity Clinic Offering an innovative well-aging method focused to generate tailored programs aiming at improving the biological age. A team of specialists operating in aspects like biochemistry and telomerase.
• Quick financial recoup
• Investment A: Associate 100'000.- / 48% ROI buy and sell agreement
• Investment B: Corporate Bond 50'000.- ...
location_on North West, United Kingdom
CanCertain enables optimal drug treatment based on a patient’s own cancer cells as opposed to current practice which relies heavily on indicative biomarkers and generic tests. CanCertain utilises protected 21st-century 3D Cell cultures technology.
• Revenue Generating Oncology Startup!
• Protected 3D Cell culture based Precision Oncology Test!
• EIS Eligible investment opportunity at an at...